Oppenheimer Starts Spruce Biosciences, Inc. (SPRB) at Outperform Dec 23, 2025 06:04AM
H.C. Wainwright Resumes Spruce Biosciences, Inc. (SPRB) at Buy Dec 22, 2025 06:20AM
Leerink Partners Upgrades Spruce Biosciences, Inc. (SPRB) to Outperform Dec 3, 2025 06:39AM
Spruce Biosciences, Inc. (SPRB) PT Raised to $259 at Citizens Nov 11, 2025 04:35AM
Citizens Upgrades Spruce Biosciences, Inc. (SPRB) to Market Outperform Oct 28, 2025 01:54AM


Oct 21, 2025 02:38PM Spruce Biosciences, Inc. (SPRB) PT Raised to $160 at Leerink Partners
Sep 15, 2025 07:02AM Spruce Biosciences resumes trading on NASDAQ Capital Market
Aug 14, 2025 04:00PM Spruce Biosciences reports positive long-term data for MPS IIIB therapy
Jun 12, 2025 08:17AM Spruce Biosciences (SPRB) Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
Apr 23, 2025 04:27AM Citizens JMP Reiterates Market Perform Rating on Spruce Biosciences, Inc. (SPRB)
Apr 15, 2025 07:02AM Spruce Biosciences (SPRB) Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B
Dec 11, 2024 08:12AM Spruce Biosciences, Inc. (SPRB) PT Lowered to $1.50 at RBC Capital Following Study Fail
Dec 11, 2024 02:54AM Oppenheimer Downgrades Spruce Biosciences, Inc. (SPRB) to Perform
Dec 11, 2024 02:53AM JMP Securities Downgrades Spruce Biosciences, Inc. (SPRB) to Market Perform
Dec 10, 2024 04:02PM Spruce Biosciences (SPRB) Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
Dec 10, 2024 04:01PM Spruce Biosciences (SPRB) Halted, News Pending
Dec 2, 2024 06:05AM Oppenheimer Reiterates Outperform Rating on Spruce Biosciences, Inc. (SPRB)
Aug 12, 2024 04:02PM Spruce Biosciences, Inc. (SPRB) Tops Q2 EPS by 10c
Jun 13, 2024 07:37AM Spruce Biosciences, Inc. (SPRB) PT Lowered to $3 at Oppenheimer